Gene Logic Drug Candidate Shows Positive In Vivo Test Results

Gene Logic announced that GL1001, the company’s clinical-stage drug candidate, showed indications of efficacy at relevant doses in in vivo testing for inflammatory bowel disease (IBD).

Based on the in vivo test results and market opportunities in IBD, the Gene Logic said it is seeking a partner for the clinical development of GL1001.

According to the company, GL1001 was found to suppress the induction of a key inflammatory mediator both in vivo and in vitro.

Gene Logic performed the work under an agreement with Millennium Pharmaceuticals and subsequently acquired certain exclusive rights to GL1001 for commercial development, the company added.